Is ESALF or QYLD a better dividend investment in 2026?

ESALF currently yields 3.60% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: QYLD offers higher current income.

What is the dividend yield difference between ESALF and QYLD?

ESALF has a forward dividend yield of 3.60% ($1.08/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 8.32 percentage points.

Home › Compare › ESALF vs QYLD

ESALF vs QYLD: Dividend Comparison 2026

ESALF yields 3.60% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 QYLD wins by $25.00 in total portfolio value· pulled ahead in Year 10

INVESTMENT

TIME HORIZON10 years

ESALF

● Live price

3.60%

Share price

$30.00

Annual div

$1.08

5Y div CAGR

0.4%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$474.23

Full ESALF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — ESALF vs QYLD

📍 QYLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ESALF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ESALF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ESALF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALF

Annual income on $10K today (after 15% tax)

$306.00/yr

After 10yr DRIP, annual income (after tax)

$403.10/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, QYLD beats the other by $4,407.32/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALF + QYLD for your $10,000?

ESALF: 50%QYLD: 50%

100% QYLD50/50100% ESALF

Portfolio after 10yr

$25.4K

Annual income

$3,066.77/yr

Blended yield

12.08%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALF buys

QYLD buys

No recent congressional trades found for ESALF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricESALFQYLD

Forward yield	3.60%	11.92% ✓
Annual dividend / share	$1.08	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0.4% ✓	0%
Portfolio after 10y	$25.4K	$25.4K
Annual income after 10y	$474.23	$5,659.31 ✓
Total dividends collected	$4.2K	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ESALF vs QYLD ($10,000, DRIP)

Year	ESALF Portfolio	ESALF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1	$11,061	$361.44	$10,352	$1,192.36	+$709.00 → ESALF
2	$12,211	$375.14	$10,830	$1,347.57	+$1.4K → ESALF
3	$13,454	$388.58	$11,460	$1,539.07	+$2.0K → ESALF
4	$14,798	$401.74	$12,275	$1,777.84	+$2.5K → ESALF
5	$16,248	$414.60	$13,323	$2,078.95	+$2.9K → ESALF
6	$17,813	$427.16	$14,667	$2,463.34	+$3.1K → ESALF
7	$19,499	$439.41	$16,396	$2,960.57	+$3.1K → ESALF
8	$21,315	$451.34	$18,631	$3,612.97	+$2.7K → ESALF
9	$23,270	$462.94	$21,548	$4,482.15	+$1.7K → ESALF
10← crossover	$25,373	$474.23	$25,398	$5,659.31	$25.00 → QYLD

ESALF vs QYLD: Complete Analysis 2026

ESALF — Stock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this ESALF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALF vs SCHD ESALF vs JEPI ESALF vs O ESALF vs KO ESALF vs MAIN ESALF vs XYLD ESALF vs JEPQ ESALF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.